Stable liquid formulations of dimer VEGF antagonists
First Claim
Patent Images
1. A stable pharmaceutical formulation comprising:
- (a) 50-100 mg/mL of a vascular endothelial growth factor (VEGF) antagonist fusion protein dimer consisting of two identical fusion polypeptides consisting essentially of (i) the immunoglobulin-like domain 2 of the human Flt1 VEGF receptor, (ii) the immunoglobulin-like domain 3 of the human Flk1 or the human Flt4 VEGF receptor, and (iii) an immunoglobulin Fc domain;
(b) 5-50 mM histidine;
(c) 0.1-3.0% polyethylene glycol (PEG) 3350;
(d) 0.24-3.0% glycine; and
(e) 0.5-6.0% sucrose, pH 6.3-6.5.
1 Assignment
0 Petitions
Accused Products
Abstract
Formulations of a vascular endothelial growth factor (VEGF)-specific fusion protein antagonist are provided including a pre-lyophilized formulation, a reconstituted lyophilized formulation, and a stable liquid formulation. Preferably, the fusion protein has the sequence of SEQ ID NO:4.
-
Citations
8 Claims
-
1. A stable pharmaceutical formulation comprising:
- (a) 50-100 mg/mL of a vascular endothelial growth factor (VEGF) antagonist fusion protein dimer consisting of two identical fusion polypeptides consisting essentially of (i) the immunoglobulin-like domain 2 of the human Flt1 VEGF receptor, (ii) the immunoglobulin-like domain 3 of the human Flk1 or the human Flt4 VEGF receptor, and (iii) an immunoglobulin Fc domain;
(b) 5-50 mM histidine;
(c) 0.1-3.0% polyethylene glycol (PEG) 3350;
(d) 0.24-3.0% glycine; and
(e) 0.5-6.0% sucrose, pH 6.3-6.5. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8)
- (a) 50-100 mg/mL of a vascular endothelial growth factor (VEGF) antagonist fusion protein dimer consisting of two identical fusion polypeptides consisting essentially of (i) the immunoglobulin-like domain 2 of the human Flt1 VEGF receptor, (ii) the immunoglobulin-like domain 3 of the human Flk1 or the human Flt4 VEGF receptor, and (iii) an immunoglobulin Fc domain;
Specification